Prolonged hypotensive effect of human tissue kallikrein gene delivery and recombinant enzyme administration in spontaneous hypertension rats

Sun, Huaichang; Zhang, Lei; Wang, Anping; Zhang, Xue

doi:10.1038/emm.2004.3

Cited by 5 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results have recently been confirmed by Sun et al [34]. Furthermore, the kallikrein gene attenuates cardiac remodeling and enhances capillary growth in SHR, through the elevation of cardiac NO, cGMP and cAMP [34]. The novel role of kallikrein/kinin, through the kinin B2 receptor, as an anti-oxidant and anti-inflammatory agent, could have further important therapeutic implications in the protection against stroke, cardiovascular and renal disease [35, 36].…”

Section: Sense To Vasodilation Genessupporting

confidence: 80%

“…Since 1997, Chao and co-workers [31,32,33] have shown that kallikrein gene delivery in SHR results in high efficiency expression and significant BP reduction. These results have recently been confirmed by Sun et al [34]. Furthermore, the kallikrein gene attenuates cardiac remodeling and enhances capillary growth in SHR, through the elevation of cardiac NO, cGMP and cAMP [34].…”

Section: Sense To Vasodilation Genessupporting

confidence: 70%

See 1 more Smart Citation

Gene-Based Therapy for Hypertension – Do Preclinical Data Suggest a Promising Future?

Puddu¹,

Cravero²,

Ferrari³

et al. 2006

Cardiology

View full text Add to dashboard Cite

Many experimental studies have obtained a prolonged control of blood pressure through gene treatment. This consists in the administration of genes coding for vasodilator proteins (the ‘sense’ approach), or of nucleotide sequences that are complementary to the mRNA of vasoconstrictor proteins, which are consequently synthesized in smaller amounts (the ‘antisense’ approach). Examples of the sense approach include the genes encoding endothelial nitric oxide synthase and kallikrein. Examples of the second type of approach are the antisense oligodeoxynucleotides to angiotensin-converting enzyme and endothelin-1. Also, RNA molecules, such as ribozymes and small interfering RNAs, are capable to inhibit RNA function. Whole sense genes are usually administered through viral vectors, while antisense oligonucleotides may be administered with plasmids or liposomes. Both viral and non-viral vectors have advantages and disadvantages. Despite the still persisting limitations, the possibility exists that in the future some forms of genetic treatment will be extended to the clinical setting, allowing a prolonged control of essential hypertension and its end-organ sequelae.

show abstract

Section: Sense To Vasodilation Genessupporting

confidence: 80%

Section: Sense To Vasodilation Genessupporting

confidence: 70%

Gene-Based Therapy for Hypertension – Do Preclinical Data Suggest a Promising Future?

Puddu¹,

Cravero²,

Ferrari³

et al. 2006

Cardiology

View full text Add to dashboard Cite

show abstract

“…reduced BP in SHR but only for 3–5 days. 125 The need for repeated delivery would increase the risk of unfavourable immunologic reactions and also compromise the expected long-lasting effect. Alternative delivery systems include the use of antisense oligodeoxynucleotides and small interfering (si)RNA.…”

Section: Gene-based Therapiesmentioning

confidence: 99%

Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches

Unger

Paulis

Sica

2011

European Heart Journal

View full text Add to dashboard Cite

The conventional antihypertensive therapies including renin–angiotensin–aldosterone system antagonists (converting enzyme inhibitors, receptor blockers, renin inhibitors, and mineralocorticoid receptor blockers), diuretics, β-blockers, and calcium channel blockers are variably successful in achieving the challenging target blood pressure values in hypertensive patients. Difficult to treat hypertension is still a commonly observed problem world-wide. A number of drugs are considered to be used as novel therapies for hypertension. Renalase supplementation, vasopeptidase inhibitors, endothelin antagonists, and especially aldosterone antagonists (aldosterone synthase inhibitors and novel selective mineralocorticoid receptor blockers) are considered an option in resistant hypertension. In addition, the aldosterone antagonists as well as (pro)renin receptor blockers or AT2 receptor agonists might attenuate end-organ damage. This array of medications has now been complemented by a number of new approaches of non-pharmacological strategies including vaccination, genomic interference, controlled breathing, baroreflex activation, and probably most successfully renal denervation techniques. However, the progress on innovative therapies seems to be slow and the problem of resistant hypertension and proper blood pressure control appears to be still persisting. Therefore the regimens of currently available drugs are being fine-tuned, resulting in the establishment of several novel fixed-dose combinations including triple combinations with the aim to facilitate proper blood pressure control. It remains an exciting question which approach will confer the best blood pressure control and risk reduction in this tricky disease.

show abstract

Management of the Hypertensive Child

Ellis

Miyashita

2014

Pediatric Nephrology

View full text Add to dashboard Cite

Prolonged hypotensive effect of human tissue kallikrein gene delivery and recombinant enzyme administration in spontaneous hypertension rats

Cited by 5 publications

References 12 publications

Gene-Based Therapy for Hypertension – Do Preclinical Data Suggest a Promising Future?

Gene-Based Therapy for Hypertension – Do Preclinical Data Suggest a Promising Future?

Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches

Management of the Hypertensive Child

Contact Info

Product

Resources

About